Relapsed/Refractory Multiple Myeloma
70
18
24
12
Key Insights
Highlights
Success Rate
43% trial completion
Published Results
13 trials with published results (19%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
22.9%
16 terminated out of 70 trials
42.9%
-43.6% vs benchmark
6%
4 trials in Phase 3/4
108%
13 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (70)
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
A Study to Evaluate the Safety and Pharmacokinetics of RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
Long-Term Follow-up Study
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma
A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Cevostamab Following CAR T Cell Therapy for RRMM
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Clinical Study on Evaluating the Safety and Effectiveness of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Third-line or Above Treatment